newsfilter
← Latest News
GlobeNewswire·

Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Patient Enrollment Advances in Global Phase 3 Program for Treatment of HCV Four Scientific Posters Presented at EASL, Including Final Results from Phase 2 Study of Bemnifosbuvir/Ruzasvir Regimen Confirming 98%